Literature DB >> 11095767

Community-Acquired Pneumonia: An Overview.

.   

Abstract

Community-acquired pneumonia (CAP) accounts for a significant number of hospitalizations and outpatient visits, as well as substantial health care expenditures. CAP is particularly common among the elderly who account for more than 90% of deaths due to pneumonia. Streptococcus pneumoniae is believed to be the most common microbial etiology of CAP, but recent studies suggest that the atypical pathogens may be more common than previously thought, particularly among ambulatory patients. Recent studies have provided data regarding risk of mortality and process of care and outcomes. Increasing resistance among strains of S. pneumoniae has impacted the approach to the empiric therapy of CAP. The Infectious Diseases Society of America published guidelines for the evaluation and management of CAP this past year. Pathogen-specific therapy guided by the results of sputum gram stain and culture is emphasized. Despite enthusiasm for practice guidelines and clinical pathways, there remains insufficient published data to determine their impact on quality and cost of care in patients with CAP.

Entities:  

Year:  1999        PMID: 11095767     DOI: 10.1007/s11908-999-0010-x

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  29 in total

1.  Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia.

Authors:  P P Gleason; W N Kapoor; R A Stone; J R Lave; D S Obrosky; R Schulz; D E Singer; C M Coley; T J Marrie; M J Fine
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

Review 2.  Community-acquired pneumonia.

Authors:  P D Brown; S A Lerner
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

3.  Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group.

Authors:  B J Marston; J F Plouffe; T M File; B A Hackman; S J Salstrom; H B Lipman; M S Kolczak; R F Breiman
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

4.  Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.

Authors:  A Ortqvist; J Hedlund; L A Burman; E Elbel; M Höfer; M Leinonen; I Lindblad; B Sundelöf; M Kalin
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

Review 5.  Pneumonia in the elderly.

Authors:  M Woodhead
Journal:  J Antimicrob Chemother       Date:  1994-08       Impact factor: 5.790

6.  Quality of care, process, and outcomes in elderly patients with pneumonia.

Authors:  T P Meehan; M J Fine; H M Krumholz; J D Scinto; D H Galusha; J T Mockalis; G F Weber; M K Petrillo; P M Houck; J M Fine
Journal:  JAMA       Date:  1997-12-17       Impact factor: 56.272

7.  Do clinical practice guidelines define good medical care? The need for good science and the disclosure of uncertainty when defining 'best practices'.

Authors:  S H Woolf
Journal:  Chest       Date:  1998-03       Impact factor: 9.410

8.  The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy.

Authors:  D C Rhew; D Hackner; L Henderson; A G Ellrodt; S R Weingarten
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

9.  Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia.

Authors:  K Gilbert; P P Gleason; D E Singer; T J Marrie; C M Coley; D S Obrosky; J R Lave; W N Kapoor; M J Fine
Journal:  Am J Med       Date:  1998-01       Impact factor: 4.965

10.  Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial.

Authors:  S J Atlas; T I Benzer; L H Borowsky; Y Chang; D C Burnham; J P Metlay; E A Halm; D E Singer
Journal:  Arch Intern Med       Date:  1998-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.